Taeniasis: Clinical Trials

8 trials for Taeniasis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 1 not yet recruiting, 1 terminated. 8 Not applicable.

By phase and status

PhaseTrialsStatus
Not applicable8Completed 6, Not yet recruiting 1, Terminated 1

Follow Taeniasis: new trials by email Literature Review of Taeniasis trials Research Report on Taeniasis

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Impact of Medical TV Drama in Improving Literacy on Neurocysticercosis
Medical TV Drama Episode (House M.D.) - Neurocysticercosis, Health Literacy
Not applicableNot yet recruitingCephas Health Research Initiative Inc, Ibadan, Nigeria602025-12-152025-12-04
Digital Health Promotion in Iringa, Tanzania
Digital health promotion intervention - HIV Infections, Tuberculosis
Not applicableCompletedUniversity of Oslo6002019-04-012020-11-04
Taenia Solium Elimination Versus Control: What is the Best Way Forward for Sub-Saharan Africa?
Mass drug administration, praziquantel 10mg/kg, Health education - Taenia Solium Infection
Not applicableCompletedInstitute of Tropical Medicine, Belgium29002016-03-012023-03-01
Taenia Solium Control Case Study in Zambia
CLTS - Cysticercosis, Helminthiasis
Not applicableCompletedUniversity of Zambia11972012-04-012015-02-11
Targeted Screening for Taenia Solium Tapeworms
Niclosamide, Community education campaign - Taenia Solium Taeniasis
Not applicableCompletedOregon Health and Science University18112011-05-012014-10-24
EFECAB: Improving Pig Management to Prevent Epilepsy in Burkina Faso
Educational package - Cysticercosis
Not applicableCompletedUniversity of Oklahoma582011-02-212018-04-03
Mass Treatment T Solium Community Study
Niclosamide - Intestinal Parasitism
Not applicableTerminatedNational Institute of Allergy and Infectious Diseases (NIAID)42002004-12-012010-08-27
Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis
albendazole, dexamethasone, phenytoin - Epilepsy, Cysticercosis
Not applicableCompletedJohns Hopkins University1202000-05-012015-03-25

Narrower conditions

Cysticercosis (5)  ·  Epilepsy (2)  ·  Neurocysticercosis (2)  ·  Cestode Infections (1)  ·  Communicable Diseases (1)  ·  HIV Infections (1)  ·  Helminthiasis (1)  ·  Immune System Diseases (1)  ·  Intestinal Diseases, Parasitic (1)  ·  Mental Disorders (1)  ·  Neurologic Manifestations (1)  ·  Parasitic Diseases (1)  ·  Rare Diseases (1)  ·  Seizures (1)

Broader conditions

Infections (8)  ·  Cestode Infections (7)  ·  Helminthiasis (7)  ·  Parasitic Diseases (7)  ·  Central Nervous System Diseases (3)  ·  Nervous System Diseases (3)  ·  Brain Diseases (2)  ·  Central Nervous System Helminthiasis (2)  ·  Central Nervous System Infections (2)  ·  Central Nervous System Parasitic Infections (2)  ·  Actinomycetales Infections (1)  ·  Bacterial Infections (1)  ·  Bacterial Infections and Mycoses (1)  ·  Blood-Borne Infections (1)

Interventions

Niclosamide (2)  ·  Albendazole (1)  ·  Dexamethasone (1)  ·  Educational Status (1)  ·  Mass Drug Administration (1)  ·  Phenytoin (1)  ·  Praziquantel (1)

Sponsors

Cephas Health Research Initiative Inc, Ibadan, Nigeria (1)  ·  Institute of Tropical Medicine, Belgium (1)  ·  Johns Hopkins University (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  Oregon Health and Science University (1)  ·  University of Oklahoma (1)  ·  University of Oslo (1)  ·  University of Zambia (1)

Countries

Peru (2)  ·  Zambia (2)  ·  Burkina Faso (1)  ·  Tanzania (1)

Top investigators

Pierre Dorny, PhD (2)  ·  Andrea S Winkler, M, PhdD (1)  ·  Armando Gonzalez, DVM PhD (1)  ·  Chummy Sikasunge, PhD (1)  ·  Emmanuel Bottieau, PhD, MD (1)  ·  Evans K. Mwape, MSc (1)  ·  Giveson Zulu, PhD (1)  ·  Robert H. Gilman (1)  ·  Sarah Gabriel, PhD (1)  ·  Seth E ONeal, MD MPH (1)

Results publications

PMID 28569208, PMID 30653519, PMID 33885369, PMID 35900820

NIH funding

R21NS069275 (1)